id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S14451 R57325 |
Breddels, 2022 | Pre-eclampsia (hypertension (systolic blood pressure>140 mmHg and/or diastolic blood pres- sure>90 mmHg) combined with proteinuria (24-h urine protein level>300 mg) | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 0.91 [0.78;1.05] | -/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S14449 R57314 |
Van Gelder, 2022 | Late-onset preeclampsia (new-onset hypertension accompanied by proteinuria after gestational week 34) | 1st and 2nd trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes | 1.10 [0.50;2.60] | 6/170 229/8,868 | 235 | 170 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12491 R47112 |
Choi (Controls exposed to other treatment, sick), 2021 | All preeclampsia (exposure window 1st trimester) | 1st trimester | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: Yes |
1.05 [0.92;1.20] excluded (control group) |
244/17,487 2,575/214,891 | 2,819 | 17,487 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12490 R47107 |
Choi (Controls unexposed NOS), 2021 | All preeclampsia (exposure window 1st trimester) | 1st trimester | population based cohort propective | unexposed (general population or NOS) | Adjustment: Yes | 1.26 [1.15;1.39] | 441/30,018 18,040/1,920,243 | 18,481 | 30,018 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 1.08 [0.81;1.44] | 18,716 | 30,188 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed NOS;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 12491